top of page
Researcher

PRIMAVERA

Start Date:

November 2021

End Date:

ongoing

Duration:

60 months

ID-CARE Role:
Website:

Partner

Description

GA Number: 101034420


Title: PrIMAVeRa  - Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance


Primary Objectives: The goal of PrIMAVeRa is to develop comprehensive mathematical models to predict the impact of vaccines and monoclonal antibodies (mAbs) on the reduction of antimicrobial resistance (AMR), thereby enabling decision-makers to prioritise the most promising new vaccines and mAbs.

A sustainability plan will also be designed by the project partners with the goal to ensure long-term access to the project results, including models, beyond the duration of the PrIMAVeRa project.

The following main goals will be addressed in an integrated manner:

  • Assessment of the availability and quality of published data and existing mathematical models of AMR

  • Setting up a comprehensive epidemiological repository

  • Development of improved mathematical models of AMR including cost-effectiveness analyses (CEA)

  • Establishment of a plan for evaluation

Partners

Ares Genetics GmbH - AUSTRIA

Danmarks Tekniske Universitet - DENMARK

Eberhard Karls Universität Tübingen - DENMARK

European Vaccine Initiative (EVI) - DENMARK

GlaxoSmithKline Biologicals SA (GSK) - BELGIUM

Hospital of Lithuanian University of Health Sciences Kauno Klinikos - LITHUANIA

Institut Pasteur - FRANCE

Institute of Health Carlos III - SPAIN

Janssen Vaccines & Prevention B.V. - NETHERLANDS

Life Science Network gGmbH - DENMARK

Pasteur Institute of Russia - RUSSIA

Pfizer - UK

Public Health England - UK

Servicio Andaluz de Salud - SPAIN

Université Grenoble Alpes - FRANCE

University Medical Center Utrecht (UMC Utrecht) - NETHERLANDS

University of Geneva - SWITZERLAND

University of Oxford - UK

Sponsor
Horizon2020.jpg
Horizon2020.jpg
Horizon2020.jpg
Horizon2020.jpg
Publications

Clinical Microbiology and Infection

19/12/23

Excess resource use and cost of drug-resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta-analysis

Clinical Microbiology and Infection

15/11/23

Frequency of bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research and discovery of new therapies in Europe: a systematic review

Clinical Microbiology and Infection

4/10/23

A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe

ID-CARE Participants

Evelina Tacconelli

Director

Jacopo Garlasco

Research Assistant

Maria Diletta Pezzani

Medical Doctor

Eva Cappelli

Clinical Research Assistant

Elena Addis

Research Assistant

Fabiana Arieti

Clinical Research Assistant & Project Manager

bottom of page